ACAD — ACADIA PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1070494 ·
Last close
$18.32
Market Cap
$3.17B
52W High
$30.96
52W Low
$15.86
ADV30
2,381,806
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 342,291,000 | 307,201,000 | 71,718,000 | 53,524,000 | 1,794,151,000 | 322,365,000 | 406,662,000 |
| Jun 2026 | 307,959,000 | 279,643,000 | 37,836,000 | 31,500,000 | 1,742,900,000 | 384,985,000 | 436,291,000 |
| Mar 2026 | 268,062,000 | 243,271,000 | -4,616,000 | 3,637,000 | 1,605,230,000 | 282,212,000 | 357,164,000 |
| Dec 2025 | 283,989,000 | 257,764,000 | 17,391,000 | 273,568,000 | 1,564,195,000 | 177,695,000 | 336,805,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$97,534,000
Investing CF
$-84,270,000
Financing CF
$49,262,000
CapEx
$-110,767,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.11
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,724,725,000
Inventory
$40,360,000
Receivables
$178,315,000
ST Investments
$654,081,000
EBIT TTM
$122,329,000
Pretax Income TTM
$157,212,000
Interest Exp TTM
—
Analysts
19
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,202,301,056
EBITDA
$135,056,000
Free Cash Flow
$46,267,624
Enterprise Value
$2,764,567,040
Total Cash
$976,446,016
Total Debt
$71,854,000
Shares Out
172,828,972
Trailing EPS
$2.12
Book Value
$8.03
ROE
31.4%
ROA
4.9%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,071,505,000 | 104,811,000 | 391,000,000 | 1,564,195,000 | 336,805,000 | 1,227,390,000 | 109,836,000 |
| Dec 2024 | 957,797,000 | 84,279,000 | 226,451,000 | 1,187,756,000 | 454,963,000 | 732,793,000 | 157,719,000 |
| Dec 2023 | 726,437,000 | -73,379,000 | -61,286,000 | 748,956,000 | 317,201,000 | 431,755,000 | 16,702,000 |
| Dec 2022 | 517,235,000 | -223,596,000 | -215,975,000 | 587,812,000 | 187,399,000 | 400,413,000 | -114,035,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$1,138,643,000
NetIncome TTM
$380,484,000
OpCashFlow TTM
—
Assets (Latest)
$1,742,900,000
Forward EPS
$1.05
Max Pain — expiry 2026-12-18
max pain strike: $20.00 · spot: $17.83 · call oi: 8,316 · put oi: 2,465
Expected Move to 2026-12-18:
±$1.70
(9.53%) —
implied range
$16.13 –
$19.53
· ATM straddle on $18.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BHC | Bausch Health Companies Inc. | $3.17B | $8.47 | — |
| LEGN | Legend Biotech Corp | $3.13B | $16.11 | — |
| BGM | BGM Group Ltd. | $3.09B | $8.13 | — |
| XERS | Xeris Biopharma Holdings, Inc. | $3.07B | $16.80 | — |
| TLX | Telix Pharmaceuticals Ltd | $3.01B | $8.85 | — |
News headlines (Yahoo Finance, 1h cache)
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
2026-11-18 03:12 · Yahoo
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease
2026-11-17 14:04 · Yahoo
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
2026-11-16 14:04 · Yahoo
Acadia Pharmaceuticals Fell While Sales Rose
2026-11-10 06:11 · Yahoo
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
2026-11-10 04:47 · Yahoo
Acadia Pharmaceuticals (ACAD) Stock Still Looks Like A Bargain Today
2026-11-10 04:29 · Yahoo
Acadia Pharmaceuticals (ACAD) Cuts 2026 R And D Guidance, Is It Still 46% Undervalued?
2026-11-10 01:17 · Yahoo
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
2026-11-09 21:05 · Yahoo
Acadia Pharmaceuticals Sees Continued Daybue Momentum in Q3, RBC Says
2026-11-05 17:07 · Yahoo
ACADIA Pharmaceuticals Inc (ACAD) Q3 2026 Earnings Call Highlights: Record Daybue Sales and ...
2026-11-05 07:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.